TNC and metastatic prostate carcinoma: In this context, PRO-C12 could be used as a tool to monitor the efficacy of anticancer treatments that disrupt the α9 integrin-tenascin-C interaction and improve the prognosis of patients with metastatic prostate cancer [73].